Skip to main content

Nektar Therapeutics

NKTR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000906709

In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 3 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.51B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Nektar Therapeutics insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
2 insiders, $441.1K in total
Insiders trading
2
Net value
−$441.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Nektar Therapeutics, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Nektar Therapeutics
NameTitleLast reported holdingLast filingFilings, past year
Whitfield Roy ADirector16,417Sep 25, 20262
Greer R ScottDirector22,239Sep 25, 20262
Chess RobertDirector19,019Sep 25, 20262
Brainard DianaDirector3,904Sep 25, 20262
Ajer Jeffrey RobertDirector4,277Sep 25, 20262
Zalevsky JonathanChief R&D Officer9,570Aug 20, 20269
Robin Howard WPresident & CEO54,627Aug 20, 20267
Wilson Mark AndrewChief Legal Officer21,585Nov 25, 20251
Kroin David10% Owner18,344,000IndirectMay 13, 20240
Deep Track Capital, LP10% Owner18,344,000IndirectMay 13, 20240
Deep Track Biotechnology Master Fund, Ltd.10% Owner18,344,000IndirectMay 13, 20240
Curet MyriamDirector27,418Sep 20, 20230
Thomsen Jillian B.Chief Financial Officer313,497Feb 17, 20230
Eastham KarinDirector23,233Sep 20, 20220
Labrucherie Gil MSVP, COO & CFO312,905May 17, 20220
Northcott JohnSVP & Chief Commercial Officer223,210May 17, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 20, 2026 (view filing)7:05 PM ETAug 182 daysZalevsky JonathanChief R&D OfficerSSale−186$71.98−$13.4K−1.9%9.57K after
Aug 20, 2026 (view filing)7:03 PM ETAug 182 daysRobin Howard WPresident & CEOSSale−418$71.98−$30.1K−0.8%54.6K after
Jul 2, 2026 (view filing)7:06 PM ETJun 302 daysZalevsky JonathanChief R&D OfficerSSale−5.68K$70.00−$397.7K−36.8%9.76K after10b5-1
Jun 18, 2026 (view filing)Jun 16-172 daysRobin Howard WPresident & CEOSSale−20.0K$60.75−$1.22M−26.7%55.0K after4 lots10b5-1
Jun 17, 2026 (view filing)Jun 152 daysZalevsky JonathanChief R&D OfficerSSale−5.54K$60.71−$336.2K−26.4%15.4K after10b5-1
May 21, 2026 (view filing)May 192 daysZalevsky JonathanChief R&D OfficerSSale−199$65.51−$13.0K−0.9%21.0K after
May 21, 2026 (view filing)May 192 daysRobin Howard WPresident & CEOSSale−444$65.51−$29.1K−0.6%75.0K after
Feb 20, 2026 (view filing)Feb 182 daysZalevsky JonathanChief R&D OfficerSSale−180$73.00−$13.1K−0.8%21.2K after
Feb 20, 2026 (view filing)Feb 182 daysRobin Howard WPresident & CEOSSale−423$73.00−$30.9K−0.6%75.5K after
Jan 22, 2026 (view filing)Jan 202 daysZalevsky JonathanChief R&D OfficerSSale−3.87K$35.67−$137.9K−15.3%21.4K after10b5-1
Nov 25, 2025 (view filing)Nov 25Same dayZalevsky JonathanChief R&D OfficerSSale−1.16K$54.28−$62.8K−5.7%19.0K after
Nov 25, 2025 (view filing)Nov 25Same dayWilson Mark AndrewChief Legal OfficerSSale−630$54.28−$34.2K−2.8%21.6K after
Nov 25, 2025 (view filing)Nov 25Same dayRobin Howard WPresident & CEOSSale−2.21K$54.28−$119.8K−3.9%54.2K after
Sep 11, 2025 (view filing)Sep 92 daysRobin Howard WPresident & CEOSSale−6.67K$46.69−$311.2K−11.9%49.3K after4 lots10b5-1
Sep 8, 2025 (view filing)Sep 44 daysZalevsky JonathanChief R&D OfficerSSale−1.72K$33.52−$57.7K−9.0%17.5K after4 lots10b5-1
Sep 8, 2025 (view filing)Sep 4-54 daysRobin Howard WPresident & CEOSSale−11.8K$36.42−$431.0K−17.4%56.0K after7 lots10b5-1
Sep 4, 2025 (view filing)Sep 22 daysZalevsky JonathanChief R&D OfficerSSale−485$30.10−$14.6K−2.5%19.2K after10b5-1
Sep 4, 2025 (view filing)Sep 22 daysRobin Howard WPresident & CEOSSale−1.50K$30.16−$45.2K−2.2%67.8K after10b5-1
Aug 21, 2025 (view filing)Aug 192 daysZalevsky JonathanChief R&D OfficerSSale−725$26.59−$19.3K−3.6%19.7K after
Aug 21, 2025 (view filing)Aug 192 daysWilson Mark AndrewChief Legal OfficerSSale−676$26.59−$18.0K−3.2%20.3K after
Aug 21, 2025 (view filing)Aug 192 daysRobin Howard WPresident & CEOSSale−1.57K$26.59−$41.8K−2.2%69.3K after
May 21, 2025 (view filing)May 192 daysZalevsky JonathanChief R&D OfficerSSale−10.7K$0.67−$7.18K−3.4%305.9K after
May 21, 2025 (view filing)May 192 daysWilson Mark AndrewChief Legal OfficerSSale−10.0K$0.67−$6.70K−3.1%314.3K after
May 21, 2025 (view filing)May 192 daysRobin Howard WPresident & CEOSSale−23.2K$0.67−$15.5K−2.1%1.06M after
Feb 21, 2025 (view filing)Feb 192 daysZalevsky JonathanChief R&D OfficerSSale−10.3K$1.01−$10.4K−3.2%316.6K after
Feb 21, 2025 (view filing)Feb 192 daysWilson Mark AndrewChief Legal OfficerSSale−11.0K$1.01−$11.2K−3.3%324.3K after
Feb 21, 2025 (view filing)Feb 192 daysRobin Howard WPresident & CEOSSale−23.8K$1.01−$24.0K−2.1%1.09M after
Dec 26, 2024 (view filing)Dec 23-243 daysWilson Mark AndrewChief Legal OfficerSSale−50.0K$0.8967−$44.8K−13.0%335.3K after2 lots
Dec 20, 2024 (view filing)Dec 191 dayZalevsky JonathanChief R&D OfficerSSale−51.1K$0.94−$48.0K−13.5%326.9K after
Dec 19, 2024 (view filing)Dec 17-182 daysRobin Howard WPresident & CEOSSale−132.0K$0.9971−$131.6K−10.6%1.11M after2 lots
Nov 20, 2024 (view filing)Nov 191 dayZalevsky JonathanChief R&D OfficerSSale−7.79K$1.01−$7.86K−3.1%243.0K after
Nov 20, 2024 (view filing)Nov 191 dayWilson Mark AndrewChief Legal OfficerSSale−6.41K$1.01−$6.47K−2.8%218.9K after
Nov 20, 2024 (view filing)Nov 191 dayRobin Howard WPresident & CEOSSale−16.3K$1.01−$16.4K−1.9%832.1K after
Aug 20, 2024 (view filing)Aug 191 dayZalevsky JonathanChief R&D OfficerSSale−6.87K$1.28−$8.79K−2.7%250.8K after
Aug 20, 2024 (view filing)Aug 191 dayWilson Mark AndrewChief Legal OfficerSSale−5.65K$1.28−$7.23K−2.4%225.3K after
Aug 20, 2024 (view filing)Aug 191 dayRobin Howard WPresident & CEOSSale−14.9K$1.28−$19.0K−1.7%848.4K after
Jun 14, 2024 (view filing)Jun 14Same dayChess RobertDirectorSSale−19.5K$1.20−$23.4K−7.1%255.3K after10b5-1
May 20, 2024 (view filing)May 173 daysRobin Howard WPresident & CEOSSale−16.6K$1.75−$29.1K−1.9%863.2K after
May 20, 2024 (view filing)May 173 daysZalevsky JonathanChief R&D OfficerSSale−7.36K$1.75−$12.9K−2.8%257.7K after
May 20, 2024 (view filing)May 173 daysWilson Mark AndrewChief Legal OfficerSSale−6.26K$1.75−$11.0K−2.6%230.4K after
May 13, 2024 (view filing)4:36 PM ETMay 103 daysKroin David and 2 others10% OwnerSSale−56.0K$1.78−$99.6K−0.3%18.3M after
Feb 22, 2024 (view filing)Feb 202 daysZalevsky JonathanChief R&D OfficerSSale−9.01K$0.68−$6.13K−3.3%265.0K after
Feb 22, 2024 (view filing)Feb 202 daysWilson Mark AndrewChief Legal OfficerSSale−7.61K$0.68−$5.17K−3.1%236.7K after
Feb 22, 2024 (view filing)Feb 202 daysRobin Howard WPresident & CEOSSale−20.0K$0.68−$13.6K−2.2%879.9K after
Nov 20, 2023 (view filing)9:02 PM ETNov 173 daysZalevsky JonathanChief R&D OfficerSSale−9.65K$0.49−$4.73K−3.4%274.0K after
Nov 20, 2023 (view filing)9:00 PM ETNov 173 daysWilson Mark AndrewChief Legal OfficerSSale−7.18K$0.49−$3.52K−2.9%243.8K after
Nov 20, 2023 (view filing)8:58 PM ETNov 173 daysRobin Howard WPresident & CEOSSale−19.9K$0.49−$9.74K−2.2%899.9K after
Sep 20, 2023 (view filing)Sep 182 daysCuret MyriamDirectorSSale−4.36K$0.69−$3.01K−13.7%27.4K after
Sep 20, 2023 (view filing)Sep 22, 2022363 daysLateChess RobertDirectorSSale−10.2K$0.67−$6.83K−3.6%274.8K after10b5-1
Sep 20, 2023 (view filing)Sep 182 daysAjer Jeffrey RobertDirectorSSale−4.36K$0.69−$3.01K−11.3%34.2K after